Although conventional tyrosine kinase inhibitors (TKI) that target the TK activity of BCR-ABL oncoprotein are the first choice of treatment for CML, the drug responses are generally short-lived, and drug resistance remains a significant clinical problem. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.